December 16, 2021 11:13 AM EST

Orencia approved by FDA for new indication — graft vs host disease; Sosei and Twist announce antibody discovery deal

Paul Schloesser

Associate Editor

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

For the first time, doctors will have a drug to combat acute graft-versus-host disease — a dangerous side effect of stem cell transplants in which donor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Orencia approved by FDA for new indication — graft vs host disease; Sosei and Twist announce antibody discovery deal

Paul Schloesser

Associate Editor

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Oren­cia ap­proved by FDA for new in­di­ca­tion — graft vs host dis­ease; So­sei and Twist an­nounce an­ti­body dis­cov­ery deal

Associate Editor

Senior Editor

Editor

Sign up to read this article for free.

Orencia approved by FDA for new indication — graft vs host disease; Sosei and Twist announce antibody discovery deal